Excellent tolerability but relatively low initial clinical efficacy of telcagepant in migraine.

@article{TfeltHansen2011ExcellentTB,
  title={Excellent tolerability but relatively low initial clinical efficacy of telcagepant in migraine.},
  author={Peer Carsten Tfelt-Hansen},
  journal={Headache},
  year={2011},
  volume={51 1},
  pages={118-23}
}
In 3 randomized clinical trials (n = 1585) the calcitonin gene-related peptide antagonist telcagepant 300 mg orally had an incidence of adverse events similar to placebo when used in the acute treatment of migraine. Telcagepant, thus, has excellent tolerability in migraine. Only a quarter (26%) (334/1307) of patients were, however, pain free after 2 hours, while 56% (729/1297) of patients had pain relief at 2 hours. Telcagepant 300 mg in one randomized clinical trial was equipotent to… CONTINUE READING